.png)
MedPage Today) -- A pembrolizumab (Keytruda) combination led to an overall survival (OS) boost in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer, according to results from the KEYNOTE-A18 trial...
Dsn.sebani Ds.tanjangrono RT 04 RW 01 Mojokerto-Jawa Timur
+6281993868686
lita@gdrive.or.id
Copyright © 2023 saktinews. All Rights Reserved
